Table 1 Baseline characteristics of COVID-19 patients.

From: Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection

 

SoC (n = 43)

ConvP (n = 43)

Male sex, n (%)

33 (77)

29 (67)

Age (years), median (IQR)

63 (55–77)

61 (56–70)

Duration of symptoms at inclusion (days), median (IQR)

11 (6–16)

9 (7–13)

Number of comorbidities, n (%)

  Diabetes mellitus

8 (19)

13 (30)

  Hypertension

11 (26)

11 (26)

  Cardiac

11 (26)

9 (21)

  Pulmonary

11 (26)

12 (28)

  Cancer

3 (7)

5 (12)

  Immunodeficiency

6 (14)

5 (12)

  Chronic kidney disease

6 (14)

1 (2)

  Liver cirrhosis

0

1 (2)

 CRP (mg/L), median (IQR)

109 (705 (12)165)

84 (50–133)

 Ferritin (µg/L), median (IQR)

709 (525–1311)

702 (406–1060)

 LDH (U/L), median (IQR)

356 (291–507)

336 (259–454)

 Lymphocytes (×109/L), median (IQR)

0.95 (0.80–1.30)

1.20 (0.80–1.53)

 Bilirubin (µmol/L), median (IQR)

8 (6–12)

9 (5–13)

WHO COVID-19 disease severity scorea, n (%)

  ≤2

0

0

  3

1 (2)

7 (16)

  4–5

34 (79)

31 (72)

  6–7

8 (19)

5 (12)

  1. aWHO 8-point COVID-19 disease severity score (at study inclusion for patients and highest score ever during disease course for donors) in which “0” is no clinical or virological evidence of infection; “1” is no limitation of activities; “2” is limitation of activities; “3” is hospitalized, no oxygen; “4” is oxygen by mask or nasal prongs; “5” is non-invasive ventilation or high-flow oxygen; “0” is intubation and mechanical ventilation; “7” is ventilation and additional organ support (vasopressors, renal replacement therapy, ECMO), and “8” is death.
Back to article page